CurrentAetnaPolicy 0517

Breast Ductal Lavage and Fiberoptic Ductoscopy

Customize your policy alerts

Sign up for Aetna Policy 0517 alerts

Get alerted when Policy 0517 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Clinical policy governing the medical necessity and investigational status of breast ductal lavage and fiberoptic ductoscopy for Aetna members, including indications, limitations, and coding guidance.

Policy Summary

PayerAetna

PolicyBreast Ductal Lavage and Fiberoptic Ductoscopy

Policy CodePolicy 0517

Change TypeNo material change

Effective Date06/15/2001

Last ReviewJul 12, 2023

Next Review Date05/23/2024

Key ActionObtain and document prior authorization when billing listed codes for covered indications and provide clinical documentation to support medical necessity.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0517

Breast Ductal Lavage and Fiberoptic Ductoscopy

Customize your policy alerts

Sign up for Aetna Policy 0517 alerts

Get alerted when Policy 0517 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAetna

PolicyBreast Ductal Lavage and Fiberoptic Ductoscopy

Policy CodePolicy 0517

Change TypeNo material change

Effective Date06/15/2001

Last ReviewJul 12, 2023

Next Review Date05/23/2024

Key ActionObtain and document prior authorization when billing listed codes for covered indications and provide clinical documentation to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

06/15/2001Effective date

07/12/2023Last review

05/23/2024Next review

3+Experimental interventions

94.2%->98.1%FD sensitivity

Coverage Criteria and Policy Position

inv-01: Medically necessary indications

Covered when ALL of the following are met

Breast ductal lavage (DL): DL is considered medically necessary as an appropriate alternative to aspiration to diagnose members with non-lactational sporadic nipple discharge when the yield of cellular material from a direct nipple aspirate is too low to permit adequate cytological analysis.

Examples of DL systems: Pro-Duct, ForeCYTE, MASCT, Halo (but screening indications are investigational).

Fiberoptic ductoscopy - diagnostic: Fiberoptic ductoscopy combined with cytology testing is considered medically necessary for diagnosing intraductal lesions in women with non-lactational sporadic nipple discharge accompanied by documented positive cytology.

Fiberoptic ductoscopy - therapeutic: Fiberoptic ductoscopy is considered medically necessary as a guide for resection of known breast intraductal cancer.

inv-02: Experimental / Investigational

The following interventions are considered experimental and investigational because effectiveness has not been established:

DL or devices for screening/ risk assessment: Breast ductal lavage and devices (e.g., Pro-Duct, ForeCYTE, Halo) are considered experimental and investigational for breast cancer screening and breast cancer risk assessment and for other indications (e.g., treatment of non-lactational mastitis).

Fiberoptic ductoscopy for screening: Fiberoptic ductoscopy (Acueity System) is considered experimental and investigational for breast cancer screening.

Combined DL and endoscopy for contralateral evaluation: Breast ductal endoscopy combined with ductal lavage for evaluation of contralateral breast in women with ipsilateral breast cancer is considered experimental/investigational.

Biomarker assays on lavage samples: Assessment of genetic methylation patterns and miRNA analysis in ductal lavage samples for prediction or detection of breast cancer are considered experimental/investigational.

inv-03: Coverage considerations

Coverage stance and considerations based on reported utility, reproducibility, and regulatory actions

General summary: DL and investigational nipple aspiration tests lack established clinical benefit as screening tools; DL has technical limitations (inconsistent NAF production, high inadequate sample rates, fair reproducibility) that limit its utility for screening or serial biomarker monitoring.

Supported by feasibility and reproducibility studies and FDA commentary.

Situations where FD/DL may have clinical value: FD can aid diagnosis and localization in patients with pathologic nipple discharge and may improve sensitivity when combined with cytology; DL/FD can be useful in research settings for biomarker discovery (metabolomic and miRNA profiling) and in select procedural contexts (e.g., guiding duct excision).

Evidence includes studies reporting high FD sensitivity and improved sensitivity with FD + cytology, and metabolomic/miRNA pilot studies.

Non-lactational mastitis: DL with intraductal infusion of corticosteroids/antimicrobials showed feasibility and a high complete response rate (93.8%) in a single-arm proof-of-concept trial; randomized controlled trial data are needed.

Use of ductal lavage (DL), nipple aspiration, or ductoscopy as a tool for population breast cancer screening is not supported by available evidence and is considered investigational/not covered. The policy notes that these interventions lack endorsement from federal public health agencies and professional organizations, and that data are insufficient to demonstrate clinical benefit as a screening test or as a routine risk‑assessment tool for asymptomatic women. Standard imaging and clinical evaluation remain the established approaches for breast cancer screening and risk assessment.

Nipple aspiration tests marketed as screening substitutes (for example, the ForeCYTE Breast Health test and related MASCT systems) are not supported by evidence and are considered investigational for breast cancer screening or risk assessment. The FDA has taken regulatory action relating to some commercial tests: a 2013 FDA warning letter cited misleading labeling for Atossa Genetics’ ForeCYTE test, and a voluntary recall was initiated in October 2013 to remove the ForeCYTE Breast Health Test from the market. These regulatory events may affect clinical availability and coverage.

The FDA has stated that the nipple aspirate test is no substitute for mammography. Unlike the cervical Pap smear, nipple aspirate testing lacks validated evidence demonstrating screening effectiveness, does not localize abnormal cells for targeted biopsy, and may produce a high proportion of samples with scant or no cellular material. Companies have reported that over 90% of nipple aspirate samples may contain very few or no cells, limiting diagnostic reliability and risking false reassurance or false positive/negative results.

Based on current evidence, DL, fiberoptic ductoscopy, and NAF-based tests used for breast cancer screening or routine risk assessment are considered not medically necessary / investigational. While DL and ductoscopy have limited roles in diagnostic contexts (see medically necessary indications), their use as screening modalities or for serial risk surveillance has not demonstrated sufficient sensitivity, reproducibility, or outcome benefit to support coverage outside of research or specified diagnostic indications.

Ductal lavage (DL) as a screening tool in asymptomatic women or for routine risk assessment is not supported due to technical and performance limitations documented in the literature: inconsistent nipple aspirate fluid (NAF) production, a high rate of inadequate cellular specimens, sub-optimal reproducibility of cytologic findings, and low sensitivity for detecting existing breast cancer. Studies report variable cannulation and cell-yield rates and fair to poor agreement for cytologic diagnosis over time, limiting the utility of DL for serial monitoring or population screening.

Coding and Billing Guidance

Other CPT codes related to the CPBCPT

19030	Injection procedure only for mammary ductogram or galactogram.
77053	Mammary ductogram or galactogram, single duct, radiological supervision and interpretation.
77054	Mammary ductogram or galactogram, multiple ducts, radiological supervision and interpretation.
88112	Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal.
88161	Cytopathology smears, any other source; preparation, screening and interpretation.

ICD-10 codes (covered if selection criteria met / not covered)ICD-10

C50.011-C50.929	Malignant neoplasm of breast [covered for known breast intraductal cancer when fiberoptic ductoscopy is used as a guide for resection only].
N64.52	Nipple discharge [non-lactational sporadic nipple discharge].
N61.0-N61.1	Inflammatory disorders of breast [non-lactational mastitis].
N63.0-N63.42	Unspecified lump in breast.
N64.3-N64.51, N64.53-N64.9	Other disorders of breast.
T85.44x+	Capsular contracture of breast implant.
Z12.39	Encounter for other screening for malignant neoplasm of breast.
Z80.3	Family history of malignant neoplasm of breast.
Z85.3	Personal history of malignant neoplasm of breast.

Gail Risk Score

Gail Risk Score threshold>= 1.7%

Context of use in studiesDooley et al (2001) and Carruthers et al (2007) enrolled women with Gail Risk score >=1.7% in ductal lavage research

Implication for high-risk cohortsUsed to define high-risk cohorts for investigational DL screening studies rather than established clinical screening

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization verification

Prior authorization verification: This bulletin is informational about Aetna's position; specific prior authorization requirements or affected codes may vary by plan. Providers should verify prior authorization requirements with the member's plan before performing breast ductal lavage or fiberoptic ductoscopy and confirm any required CPT/HCPCS/ICD-10 codes and documentation needed for medical necessity review.

Verify prior authorization requirements with the member's plan prior to service.
Confirm the exact CPT/HCPCS/ICD-10 codes to be billed and whether they are subject to code-based prior authorization.

Prior Authorization

Prior authorization for ductoscopy

Prior authorization for ductoscopy: Prior authorization may be appropriate when ductoscopy is performed for evaluation of pathological (non-lactational) nipple discharge or to guide excision of known intraductal cancer. When required, approval should be supported by documentation of indication, prior noninvasive imaging, and cytology results as applicable.

Ductoscopy for evaluation of pathological nipple discharge (e.g., spontaneous, unilateral, bloody or serous discharge).

Background and Rationale

Background: Breast ductal lavage (DL) and nipple aspirate fluid (NAF) collection are techniques intended to obtain epithelial cells from the lactiferous ducts for cytologic examination or biomarker testing. DL typically involves catheterization of ducts with saline infusion to wash and collect ductal epithelial cells, while NAF collection uses noninvasive suction devices (examples include the Halo and ForeCYTE systems). Although some specimen‑collection devices have received FDA 510(k) clearance for collection, evidence supporting clinical effectiveness of DL/NAF testing as screening tools is insufficient, and major guideline bodies and federal agencies do not recommend DL for breast cancer screening outside of research settings.

Breast ductal lavage — definition

DefinitionBreast ductal lavage (DL) is catheterization of individual breast ducts with saline infusion to wash and collect ductal epithelial cells for cytologic analysis.

Technique overviewAfter topical anesthetic and nipple suction to identify duct orifices, a microcatheter is threaded into the duct, saline is infused, the breast massaged, and lavage fluid with cells is recovered for cytology.

Common device examplesDevices mentioned include Pro-Duct Catheter, ForeCYTE, MASCT, and Halo systems (device clearance noted via 510(k) for some devices).

Molecular / Biomarker Notes and Research Findings

Biomarker list (methylation, miRNA, metabolomics)

Genetic methylation patternsPromoter and gene methylation patterns (e.g., p16, RASSF1A, RARbeta, hTERT) assessed in ductal fluid samples.

microRNA (miRNA)miRNA expression profiling from ductal lavage or nipple aspirate fluid for potential detection or characterization of breast cancer.

Metabolomic signaturesMetabolites and untargeted metabolomic ion profiles identified in ductal fluid as candidate biomarkers (e.g., ions identified by UPLC‑QTOF analyses).

Other molecular markersAdditional molecular markers evaluated include DNA methylation panels and other genomic/epigenetic alterations in research studies.

miRNA and metabolomic signatures — diagnostic accuracy

miRNA diagnostic potential

Line of Therapy / Use Context

inv-31: salvage

Use as surgical guide (salvage): Fiberoptic ductoscopy may be used as a guide for resection of known breast intraductal cancer.

Policy Summary

PayerAetna

PolicyBreast Ductal Lavage and Fiberoptic Ductoscopy

Policy CodePolicy 0517

Change TypeNo material change

Effective Date06/15/2001

Last ReviewJul 12, 2023

Next Review Date05/23/2024

Key ActionObtain and document prior authorization when billing listed codes for covered indications and provide clinical documentation to support medical necessity.

SourceLink

On This Page

Chen et al. 2019 proof-of-concept trial.

Investigational/market status: Commercial nipple aspirate tests (e.g., ForeCYTE/MASCT) have had regulatory issues (FDA warning, voluntary recall) and are not established replacements for mammography or clinical breast exam.

FDA warning letter and voluntary recall reported.

Ductoscopy used as an intraoperative guide for resection of known intraductal breast cancer (coverage limited to that indication).

Documentation Required

Procedure and testing documentation

Required clinical and procedure documentation: When ductal lavage or fiberoptic ductoscopy is performed for a medically necessary indication, submit documentation that supports the indication and medical necessity. Documentation should be sufficient for retrospective review if requested.

Indication for procedure (e.g., spontaneous, unilateral non-lactational nipple discharge; known intraductal cancer when ductoscopy is used to guide resection).
Prior diagnostic workup including clinical exam, mammography and/or targeted breast ultrasound results.
Cytology results when combined with ductoscopy (positive cytology when applicable).
Procedure note describing technique, ducts examined, findings (visualized lesions, papillomas, masses), specimens collected, and operative guidance if ductoscopy was used during resection.
For ductal lavage as an alternative to aspiration: documentation that nipple aspirate yield was inadequate for cytology.
Follow-up plan and any pathology or tissue diagnosis obtained after the procedure.

Note

Regulatory action may impact coverage

Regulatory action may impact coverage: Tests or devices removed from the market or subject to regulatory action (for example, the ForeCYTE Breast Health Test was voluntarily recalled after FDA enforcement action) may affect whether certain marketed ductal lavage products or test panels are considered acceptable for clinical use or covered by the plan. Verify that the specific test/device is marketed with appropriate regulatory status and provide supporting documentation when seeking coverage.

If a named test or system (e.g., ForeCYTE, MASCT, Pro-Duct, Halo) has been recalled, withdrawn, or received an FDA warning, expect coverage determination to reflect that regulatory status.
Provide current device/test labeling and regulatory status when requesting prior authorization or claim review.

Note

Provider responsibilities and clinical judgment

Treating providers are responsible for medical advice and treatment; the information in this Clinical Policy Bulletin is intended to assist in administering plan benefits and is not a substitute for clinical judgment. Providers are responsible for ensuring that members receive appropriate clinical care and for supplying complete documentation to support medical necessity when requesting prior authorization or when claims are audited.

Providers must counsel members on the risks, benefits, and alternatives to ductal lavage or ductoscopy.
Submit complete medical records and test results to support any request for coverage or prior authorization.
Clinical Policy Bulletins do not constitute guarantees of coverage — final determinations are made according to individual plan provisions.

Nipple aspirate fluid (NAF)

DefinitionNipple aspirate fluid (NAF) collection uses noninvasive suction to obtain small amounts of ductal fluid and cells from the nipple for cytology.

Device examplesExamples include the HALO NAF Collection System and the ForeCYTE Breast Health test (ForeCYTE has had regulatory issues including recall/actions).

Sample limitationsTypically obtains only tiny fluid volumes and few cells, resulting in high rates of scant or acellular samples and limiting diagnostic utility.

Fiberoptic ductoscopy — definition

DefinitionFiberoptic ductoscopy (mammary endoscopy) is insertion of a small fiberoptic scope through the nipple ductal opening to visualize the intraductal system.

Primary purposeUsed to detect intraductal abnormalities and can be combined with cytology or used to guide resection of intraductal cancer.

Alternate nameAlso referred to as mammary endoscopy or ductoscopy (Acueity System referenced).

Fiberoptic ductoscopy (FD) — procedural descriptor

Procedural descriptorA small, pencil-tip fiberoptic scope is inserted into the nipple duct to project high-resolution video images of the ductal lumen for detection and localization of lesions as small as 0.1 mm.

Clinical rolesCan be used diagnostically for patients with pathologic nipple discharge and therapeutically to guide duct excision of known intraductal cancer.

Research statusAcueity System and similar ductoscopes are used in research and clinical trials; safety and effectiveness not demonstrated in randomized controlled trials for screening.

Ductal lavage (DL) — collection description

Collection descriptionDuctal lavage involves locating duct orifices, threading a flexible microcatheter into the duct, infusing saline, massaging the breast to dislodge cells, and retrieving saline with epithelial cells for cytologic analysis.

Anesthesia and stepsTopical anesthetic applied to nipple, suction used to identify ducts, anesthetic inserted into duct before catheter placement—saline wash collected via microcatheter.

Intended specimen useRecovered fluid and cellular material are separated and analyzed cytologically to identify atypical or malignant ductal cells.

Ductal lavage / mammary ductoscopy — combined descriptor

Combined descriptorDuctal lavage and mammary ductoscopy encompass endoscopic visualization of ducts and lavage-based collection of ductal fluid/cells for cytology, biomarker analysis, or localization/biopsy of intraductal pathology.

Use casesMay be applied to diagnosis/localization in pathologic nipple discharge, biomarker discovery (metabolomic/miRNA studies), or to guide surgical excision in select cases.

Research emphasisCombination approaches have been described as feasible particularly in research settings, but clinical value for screening or routine risk assessment is unestablished.

Pilot studies show differential miRNA expression in DL fluid between tumor and paired normal samples, suggesting feasibility for detection of breast cancer.

Metabolomic model accuracyAn untargeted metabolomic analysis of ductal fluid reported strong discrimination between affected and control breasts (reported high AUC in study results).

Interpretation caveatFindings are preliminary with variability across studies; these approaches remain investigational and are primarily research tools at present.

Promoter methylation examples

Promoter methylation targetsExamples assessed in DL samples include p16, RASSF1A, twist, and RARbeta promoter methylation.

Association findingsAntill et al reported associations between p16 methylation and BRCA1 mutation status and between RASSF1A methylation and cancer development in study samples.

Research implicationPromoter methylation patterns could potentially predict future breast cancer risk but require further corroboration.

Molecular markers — research summary

Research summaryMultiple molecular markers (DNA methylation, microRNA profiles, hTERT methylation) have been evaluated in DL/ductal fluid as potential biomarkers for breast cancer detection and risk assessment.

Study limitationsStudies are generally pilot or feasibility in nature with variability between results; robust prospective validation is lacking.

Current roleThese molecular assays are considered investigational when applied to lavage samples and are appropriate primarily in research settings rather than routine clinical practice.